7:55 AM
 | 
Nov 16, 2018
 |  BC Week In Review  |  Financial News  |  Completed Offerings

Hillhouse, Quan lead $93M series B for immuno-oncology play NextCure

NextCure Inc. (Beltsville, Md.) raised $93 million on Nov. 13 in a series B round led by new investors Hillhouse Capital Management and Quan Capital to fund development of its two lead immuno-oncology candidates.

PD-1 pioneer Lieping Chen helped found NextCure in 2015 to develop new checkpoint inhibitors to treat patients who don't respond to PD-1 or PD-L1 inhibitors (see "Next, After T Cells").

The company's NC318 is an antibody against sialic acid binding Ig like...

Read the full 361 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >